Traders should monitor Vafseo's commercial momentum in 2026, particularly patient access expansion and adherence improvements from observed dosing protocols. The anticipated decline in Auryxia revenues due to generic competition could pressure margins, but strong Vafseo growth and robust cash reserves provide runway for pipeline development.
AKBA drugs
AKBA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $1.32entry
- T+1 · 9mo ago −0.76%α −0.30% · $1.31
- T+5 · 9mo ago −9.85%α −8.72% · $1.19
- T+20 · 8mo ago +5.30%α +11.71% · $1.39
- T+60 · 6mo ago −22.73%α −30.48% · $1.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenues of $57.6 million (Q4) and $236.2 million (full-year), representing significant year-over-year growth. The increase was driven by Vafseo sales following its 2025 U.S. launch and higher Auryxia volumes. The company reported a reduced net loss and expects Vafseo revenue growth in 2026 due to expanded access and improved adherence, though Auryxia revenues are expected to decline due to generic competition.
Key Financial Metrics
Key Facts
- Q4 2025 total revenues: $57.6 million (up from $46.5 million in Q4 2024)
- Full-year 2025 total revenues: $236.2 million (up from $160.2 million in 2024)
- Vafseo net product revenues: $6.2 million in Q4 2025 and $45.8 million for full-year 2025
- Auryxia net product revenues: $48.1 million in Q4 2025 (up from $44.4 million in Q4 2024)
- Net loss reduced to $12.2 million in Q4 2025 from $22.8 million in Q4 2024
- Cash and cash equivalents: $184.8 million as of December 31, 2025 (up from $51.9 million in 2024)
- Company expects significant Vafseo revenue growth in 2026 but anticipates Auryxia revenue decline due to generic competition
Financial Impact
Total revenues increased 24% YoY in Q4 and 48% YoY for full-year 2025, with net loss reduced by 46% YoY in Q4. Cash position increased by $132.9 million year-over-year.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Vafseo | $45.8M | Not reported |
| Auryxia | $181.5M | +19.3% |
Risk Factors
- Auryxia revenues expected to decrease in 2026 due to expanding generic competition
- Vafseo carries a boxed warning for increased risk of death, MI, stroke, and thrombosis
- Forward-looking statements about Vafseo revenue growth are subject to commercial execution risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001517022-26-000019 |
| Document: akba-20260226.htm | 0001517022-26-000019 |
| Document: 0001517022-26-000019-index-headers.html | 0001517022-26-000019 |
| Document: 0001517022-26-000019-index.html | 0001517022-26-000019 |
| Document: 0001517022-26-000019.txt | 0001517022-26-000019 |
Track record
11 reports on AKBA
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +14.04% at T+5 after the Jun 30, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry $0.4700 Now $0.4490 −4.47% settles Nov 17
- Nov 16, 2026today Press Release Neutral 3/10 Entry $0.4775 Now $0.4490 −5.97% settles Nov 17
- Nov 5, 202611d ago 8-K Bearish 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $0.4255 to $0.4013 Now $0.4490 −5.52% ▲ +5.69% +6.00% vs SPY
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $0.6438 to $0.6604 Now $0.4490 −30.26% ▲ +2.58% +2.02% vs SPY
- Oct 23, 202624d ago 8-K Bearish 7/10 Entry $0.6438 to $0.6604 Now $0.4490 +30.26% ▼ −2.58% −2.02% vs SPY
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.7020 to $0.6955 Now $0.4490 −36.04% ▼ −0.93% −1.21% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9800 to $0.9326 Now $0.4490 −54.18% ▼ −4.84% −4.12% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $1.14 to $1.21 Now $0.4490 −60.61% ▲ +6.14% +6.28% vs SPY
- Apr 30, 202628w ago Press Release Neutral 1/10 Entry $1.40 Now $0.4490 −67.93% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers